Comment to: “Randomized Phase 3 Study of Triheptanoin for Glut1 Deficiency Syndrome–Associated Paroxysmal Movement Disorders”

Ähnliche Einträge

• Reply to: Comment on De Giorgis et al. “Randomized Phase 3 Study of Triheptanoin for Glut1 Deficiency Syndrome–Associated Paroxysmal Movement Disorders”
  von: Valentina De Giorgis, et al.
  Veröffentlicht: (2024)
• Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 Study
  von: Valentina De Giorgis, et al.
  Veröffentlicht: (2024)
• Comment on Schwarz et al. “EFNB3 Frameshift Variant in Weimaraner Dogs with a Condition Resembling a Congenital Mirror Movement Disorder”
  von: Oriane Trouillard, et al.
  Veröffentlicht: (2025)
• Comment on “Defining the Genetic Landscape of Congenital Mirror Movements in 80 Affected Individuals”
  von: Oriane Trouillard, et al.
  Veröffentlicht: (2024)
• Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease
  von: Sacha Brohée, et al.
  Veröffentlicht: (2025)